AAM Urges FDA To Reassess Nitrosamines

Generics Industry Body Proposes Science-Driven, Risk-Based Approach

 
• By Akriti Seth

The AAM has published a position paper on nitrosamines that urges the FDA to revisit and reassess its safety limits for nitrosamines in pharmaceuticals, while also proposing a “science-driven” risk-based approach to evaluate drugs for the potential presence of nitrosamines.

International Carcinogen Hazard Symbol,Yellow warning Dangerous icon isolated on white background, Attracting attention, Compulsory, Control, practice, Security first sign, Vector, EPS10
The generics industry proposes proactive actions to FDA to mitigate nitrosamine-related challenges • Source: Shutterstock

More from Generics

More from Products